Symbols / DMRA Stock $23.77 -1.90% Damora Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
DMRA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Jennifer A. Jarrett M.B.A.
Exch · Country NCM · United States
Market Cap 1.43B
Enterprise Value 1.62B
Income -209.84M
Sales —
FCF (ttm) -3.05M
Book/sh -110.11
Cash/sh 4.27
Employees 7
Insider 10d —
IPO Oct 29, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -9.74
PEG —
P/S —
P/B -0.22
P/C —
EV/EBITDA -44.33
EV/Sales —
Quick Ratio 12.88
Current Ratio 12.98
Debt/Eq 0.03
LT Debt/Eq —
EPS (ttm) -3.98
EPS next Y -2.44
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-03-19
Earnings (prior) 2025-03-19
ROA -16.46%
ROE -163.80%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 60.30M
Shs Float 43.75M
Insider Own 7.85%
Instit Own 8.17%
Short Float 1.86%
Short Ratio 3.78
Short Interest 1.12M
52W High 38.33
vs 52W High -37.98%
52W Low 2.45
vs 52W Low 870.20%
Beta 1.60
Impl. Vol. —
Rel Volume 0.08
Avg Volume 302.35K
Volume 25.70K
Target (mean) $45.17
Tgt Median $45.00
Tgt Low $40.00
Tgt High $55.00
# Analysts 6
Recom Strong_buy
Prev Close $24.23
Price $23.77
Change -1.90%
About

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$45.17
Mean price target
2. Current target
$23.77
Latest analyst target
3. DCF / Fair value
$-0.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$23.77
Low
$40.00
High
$55.00
Mean
$45.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-24 init RBC Capital — → Outperform $40
2026-03-25 init Evercore ISI Group — → Outperform $46
2026-02-17 init UBS — → Buy $45
2026-02-17 main Guggenheim Buy → Buy $40
2026-01-07 init Leerink Partners — → Outperform $46
2025-12-08 main Guggenheim Buy → Buy $36
2025-12-01 init Guggenheim — → Buy $32
News
RSS: Latest DMRA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-30 JARRETT A JENNIFER Chief Executive Officer — 500,000 $0.00 $0
2026-02-09 FAIRMOUNT FUNDS MANAGEMENT LLC Director and Beneficial Owner of more than 10% of a Class of Security — 8,713,000 — —
2026-02-09 BRUNO JULIANNE Director — 129,000 — —
2026-01-05 HEWES LEMUEL BECKER Officer — 264,629 $0.00 $0
2026-01-05 SATTARZADEH SHERWIN Chief Operating Officer — 190,376 $0.00 $0
2026-01-02 SCHAMBYE HANS T. Chief Executive Officer — 700 $21.38 $14,966
2026-01-02 SCHAMBYE HANS T. Chief Executive Officer — 1,360 — —
2026-01-02 WINSLOW GARRETT General Counsel — 255 $21.38 $5,452
2026-01-02 WINSLOW GARRETT General Counsel — 680 — —
2026-01-02 FIRMANI LORI Chief Financial Officer — 135 $21.41 $2,890
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
210.87
+890.38%
21.29
-41.60%
36.46
-40.44%
61.21
Research And Development
201.19
+1764.05%
10.79
-54.59%
23.77
-50.69%
48.21
Selling General And Administration
9.69
-7.75%
10.50
-17.25%
12.69
-2.42%
13.00
General And Administrative Expense
9.69
-7.75%
10.50
-17.25%
12.69
-2.42%
13.00
Other Gand A
9.69
-7.75%
10.50
-17.25%
12.69
-2.42%
13.00
Total Expenses
210.87
+890.38%
21.29
-41.60%
36.46
-40.44%
61.21
Operating Income
-210.87
-890.38%
-21.29
+41.60%
-36.46
+40.44%
-61.21
Total Operating Income As Reported
-210.87
-847.31%
-22.26
+44.22%
-39.91
+34.80%
-61.21
EBITDA
-210.84
-898.71%
-21.11
+40.74%
-35.63
+41.32%
-60.72
Normalized EBITDA
-210.75
-945.35%
-20.16
+37.09%
-32.05
+46.21%
-59.58
Reconciled Depreciation
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
EBIT
-210.87
-890.38%
-21.29
+41.60%
-36.46
+40.44%
-61.21
Total Unusual Items
-0.08
+91.16%
-0.95
+73.47%
-3.58
-214.40%
-1.14
Total Unusual Items Excluding Goodwill
-0.08
+91.16%
-0.95
+73.47%
-3.58
-214.40%
-1.14
Special Income Charges
0.00
+100.00%
-0.97
+71.39%
-3.38
0.00
Restructuring And Mergern Acquisition
0.00
-100.00%
0.97
-71.93%
3.45
0.00
Net Income
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Pretax Income
-209.79
-880.41%
-21.40
+44.20%
-38.35
+37.77%
-61.62
Net Non Operating Interest Income Expense
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Net Interest Income
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Interest Income Non Operating
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Interest Income
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Other Income Expense
-0.08
+91.16%
-0.95
+73.47%
-3.58
-214.40%
-1.14
Gain On Sale Of Security
-0.08
-566.67%
0.02
+109.14%
-0.20
+82.70%
-1.14
Tax Provision
0.05
+21.95%
0.04
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Net Income From Continuing Operation Net Minority Interest
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Net Income From Continuing And Discontinued Operation
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Net Income Continuous Operations
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Normalized Income
-209.75
-923.74%
-20.49
+41.07%
-34.77
+42.52%
-60.48
Net Income Common Stockholders
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Diluted EPS
—
-18.53
+48.64%
-36.08
+40.61%
-60.75
Basic EPS
—
-18.53
+48.64%
-36.08
+40.61%
-60.75
Basic Average Shares
—
1.16
+8.87%
1.06
+4.58%
1.02
Diluted Average Shares
—
1.16
+8.87%
1.06
+4.58%
1.02
Diluted NI Availto Com Stockholders
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Gain On Sale Of PPE
—
0.00
-100.00%
0.06
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
260.53
+1420.70%
17.13
-55.18%
38.23
-47.77%
73.19
Current Assets
260.42
+1446.55%
16.84
-54.21%
36.77
-42.46%
63.91
Cash Cash Equivalents And Short Term Investments
257.62
+1717.45%
14.18
-57.24%
33.15
-44.95%
60.22
Cash And Cash Equivalents
257.62
+1717.45%
14.18
-33.96%
21.46
-34.53%
32.79
Other Short Term Investments
—
0.00
-100.00%
11.69
-57.41%
27.44
Receivables
0.90
+2.04%
0.88
-48.72%
1.72
+24.58%
1.38
Taxes Receivable
0.90
+2.04%
0.88
-48.72%
1.72
+24.58%
1.38
Prepaid Assets
0.58
-2.20%
0.59
-23.77%
0.77
-3.85%
0.81
Current Deferred Assets
1.20
+8.61%
1.10
+5.45%
1.05
-27.86%
1.45
Other Current Assets
0.12
+38.89%
0.09
+5.88%
0.09
+63.46%
0.05
Total Non Current Assets
0.10
-64.51%
0.29
-79.83%
1.45
-84.34%
9.28
Net PPE
0.10
-20.00%
0.13
-60.00%
0.33
-72.15%
1.17
Gross PPE
0.18
-2.22%
0.18
-49.15%
0.35
-71.20%
1.23
Accumulated Depreciation
-0.07
-44.00%
-0.05
-72.41%
-0.03
+53.23%
-0.06
Machinery Furniture Equipment
—
—
—
—
Other Properties
0.18
-2.22%
0.18
-49.15%
0.35
-71.20%
1.23
Investments And Advances
—
—
0.00
-100.00%
5.83
Other Investments
—
—
—
5.83
Other Non Current Assets
—
0.16
-85.55%
1.13
-50.50%
2.28
Total Liabilities Net Minority Interest
20.15
+1448.58%
1.30
-77.93%
5.90
-48.44%
11.44
Current Liabilities
20.07
+1576.36%
1.20
-79.47%
5.83
-47.51%
11.11
Payables And Accrued Expenses
18.53
+3569.11%
0.51
-87.75%
4.12
-56.60%
9.49
Payables
17.66
+4585.68%
0.38
-77.85%
1.70
-49.19%
3.35
Accounts Payable
0.44
+17.77%
0.38
-77.85%
1.70
-49.19%
3.35
Other Payable
17.22
—
—
—
Current Accrued Expenses
0.86
+575.00%
0.13
-94.71%
2.42
-60.63%
6.14
Pensionand Other Post Retirement Benefit Plans Current
0.44
+116.67%
0.20
-79.33%
0.99
+65.33%
0.60
Current Debt And Capital Lease Obligation
0.01
+25.00%
0.01
-93.44%
0.18
-61.55%
0.48
Current Capital Lease Obligation
0.01
+25.00%
0.01
-93.44%
0.18
-61.55%
0.48
Other Current Liabilities
1.08
+126.89%
0.48
-11.69%
0.54
+0.00%
0.54
Total Non Current Liabilities Net Minority Interest
0.08
-22.12%
0.10
+57.58%
0.07
-79.88%
0.33
Long Term Debt And Capital Lease Obligation
0.05
-13.11%
0.06
-7.58%
0.07
-79.88%
0.33
Long Term Capital Lease Obligation
0.05
-13.11%
0.06
-7.58%
0.07
-79.88%
0.33
Other Non Current Liabilities
0.03
-34.88%
0.04
—
—
Stockholders Equity
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Common Stock Equity
-175.87
-1315.35%
14.47
-55.24%
32.33
-47.64%
61.75
Capital Stock
416.25
+30506.84%
1.36
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
416.25
+30506.84%
1.36
0.00
0.00
Share Issued
1.60
+21.29%
1.32
+21.44%
1.08
+5.69%
1.03
Ordinary Shares Number
1.60
+21.29%
1.32
+21.44%
1.08
+5.69%
1.03
Additional Paid In Capital
310.69
+6.44%
291.90
+1.34%
288.04
+2.97%
279.73
Retained Earnings
-487.36
-75.61%
-277.52
-8.37%
-256.08
-17.61%
-217.74
Gains Losses Not Affecting Retained Earnings
0.80
+726.80%
0.10
-74.47%
0.38
+255.74%
-0.24
Other Equity Adjustments
0.80
+726.80%
0.10
-74.47%
0.38
+255.74%
-0.24
Total Equity Gross Minority Interest
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Total Capitalization
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Working Capital
240.36
+1436.61%
15.64
-49.45%
30.94
-41.40%
52.80
Invested Capital
-175.87
-1315.35%
14.47
-55.24%
32.33
-47.64%
61.75
Total Debt
0.07
-6.85%
0.07
-70.68%
0.25
-69.03%
0.80
Capital Lease Obligations
0.07
-6.85%
0.07
-70.68%
0.25
-69.03%
0.80
Net Tangible Assets
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Tangible Book Value
-175.87
-1315.35%
14.47
-55.24%
32.33
-47.64%
61.75
Available For Sale Securities
—
—
—
5.83
Investmentin Financial Assets
—
—
0.00
-100.00%
5.83
Preferred Stock Equity
416.25
+30506.84%
1.36
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.73
+63.88%
-18.62
+49.55%
-36.91
+14.02%
-42.93
Cash Flow From Continuing Operating Activities
-6.73
+63.88%
-18.62
+49.55%
-36.91
+14.02%
-42.93
Net Income From Continuing Operations
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Depreciation Amortization Depletion
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
Depreciation
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
Depreciation And Amortization
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
Other Non Cash Items
174.35
+8648.37%
1.99
+4232.61%
0.05
-20.69%
0.06
Stock Based Compensation
1.00
-69.19%
3.24
-40.32%
5.43
-2.58%
5.57
Operating Gains Losses
9.36
—
-0.06
-191.43%
0.07
Gain Loss On Investment Securities
9.36
—
—
0.07
Gain Loss On Sale Of PPE
—
0.00
+100.00%
-0.06
0.00
Change In Working Capital
18.36
+788.56%
-2.67
+38.97%
-4.37
-136.61%
11.94
Change In Prepaid Assets
-0.14
-114.47%
0.95
+1367.69%
0.07
-98.96%
6.23
Change In Payables And Accrued Expense
18.37
+511.54%
-4.46
+10.42%
-4.98
-176.84%
6.49
Change In Accrued Expense
1.10
+135.01%
-3.14
+5.88%
-3.33
-171.47%
4.67
Change In Payable
17.27
+1403.55%
-1.32
+19.60%
-1.65
-190.60%
1.82
Change In Account Payable
17.27
+1403.55%
-1.32
+19.60%
-1.65
-190.60%
1.82
Change In Other Current Assets
0.17
-82.89%
0.97
-15.51%
1.15
+546.69%
-0.26
Change In Other Current Liabilities
-0.04
+72.44%
-0.13
+78.83%
-0.60
-14.72%
-0.52
Investing Cash Flow
-17.37
-249.13%
11.65
-47.83%
22.33
+80.31%
12.38
Cash Flow From Continuing Investing Activities
-17.37
-249.13%
11.65
-47.83%
22.33
+80.31%
12.38
Net PPE Purchase And Sale
—
0.00
-100.00%
0.08
+142.35%
-0.20
Purchase Of PPE
—
—
0.00
+100.00%
-0.20
Sale Of PPE
—
0.00
-100.00%
0.08
0.00
Capital Expenditure
—
—
—
-0.20
Net Investment Purchase And Sale
0.00
-100.00%
11.65
-47.63%
22.25
+76.84%
12.58
Purchase Of Investment
—
0.00
+100.00%
-25.94
+42.19%
-44.87
Sale Of Investment
0.00
-100.00%
11.65
-75.82%
48.18
-16.12%
57.45
Net Business Purchase And Sale
-17.37
0.00
—
—
Purchase Of Business
-17.37
0.00
—
—
Financing Cash Flow
266.84
0.00
-100.00%
2.88
+467.26%
0.51
Cash Flow From Continuing Financing Activities
266.84
0.00
-100.00%
2.88
+467.26%
0.51
Net Common Stock Issuance
—
0.00
-100.00%
2.88
+467.26%
0.51
Proceeds From Stock Option Exercised
0.03
0.00
—
—
Changes In Cash
242.74
+3581.20%
-6.97
+40.43%
-11.71
+61.04%
-30.04
Effect Of Exchange Rate Changes
0.70
+322.40%
-0.32
-182.55%
0.38
+45.45%
0.26
Beginning Cash Position
14.18
-33.96%
21.46
-34.53%
32.79
-47.60%
62.56
End Cash Position
257.62
+1717.45%
14.18
-33.96%
21.46
-34.53%
32.79
Free Cash Flow
-6.73
+63.88%
-18.62
+49.55%
-36.91
+14.42%
-43.13
Income Tax Paid Supplemental Data
0.01
0.00
0.00
0.00
Amortization Of Securities
0.00
-100.00%
0.07
+116.24%
-0.43
-176.15%
0.57
Common Stock Issuance
—
0.00
-100.00%
2.88
+467.26%
0.51
Issuance Of Capital Stock
266.81
0.00
-100.00%
2.88
+467.26%
0.51
Net Preferred Stock Issuance
266.81
0.00
—
—
Preferred Stock Issuance
266.81
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category